Strategy for Targeting the Undruggable
“The University of Texas MD Anderson Cancer Center and start up Nexo Therapeutics have announced a multi-year strategic collaboration for new cancer therapies against previously undruggable targets. The agreement links Nexo’s drug discovery platform, which combines innovative covalent chemistry and chemical biology, with MD Anderson’s expertise in translational research and drug development. . . . The company’s chemical biology approach, INFINI-T (Informed Profile Before Initiation of Target), uses chimeric fusion proteins to address target biology and pharmacology questions. The function of these chimeric proteins is controlled by small molecules in cellular and in vivo models to generate detailed information about the required depth, duration and selectivity of target inhibition. They point out that the INFINI-T platform provides target product profiles for medicinal chemistry well in advance of lead optimization.” MORE
Image Credit: InsidePrecisionMedicine.com